Walleye Capital LLC Invests $681,000 in REGENXBIO Inc. (NASDAQ:RGNX)

Walleye Capital LLC acquired a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 88,148 shares of the biotechnology company’s stock, valued at approximately $681,000.

Several other hedge funds have also added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its holdings in shares of REGENXBIO by 67.0% in the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company’s stock worth $31,975,000 after purchasing an additional 1,659,206 shares during the period. Norges Bank bought a new position in shares of REGENXBIO during the 4th quarter worth $3,474,000. Assenagon Asset Management S.A. increased its holdings in REGENXBIO by 53.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock worth $6,621,000 after acquiring an additional 296,700 shares during the last quarter. Renaissance Technologies LLC bought a new stake in REGENXBIO in the 4th quarter valued at about $2,097,000. Finally, Trexquant Investment LP purchased a new stake in REGENXBIO during the fourth quarter valued at about $1,160,000. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Stock Performance

NASDAQ:RGNX opened at $7.82 on Wednesday. REGENXBIO Inc. has a 52-week low of $5.04 and a 52-week high of $17.52. The stock has a fifty day moving average of $6.81 and a 200 day moving average of $8.11. The firm has a market capitalization of $391.91 million, a price-to-earnings ratio of -1.55 and a beta of 1.26.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The firm had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million. Equities analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on RGNX. HC Wainwright reduced their target price on shares of REGENXBIO from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Monday, March 17th. Chardan Capital reissued a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a report on Thursday, March 20th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $30.00 price target on shares of REGENXBIO in a report on Tuesday, January 21st. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, March 7th. Finally, The Goldman Sachs Group reduced their target price on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, April 17th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.63.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.